Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) executed an on-market repurchase of 420,000 A shares on 4 June 2026 via the Shanghai Stock Exchange.

The shares were acquired at prices between RMB 46.70 and RMB 47.70, resulting in a total consideration of RMB 19.82 million and a volume-weighted average cost of RMB 47.20 per share. All repurchased stock has been earmarked as treasury shares for the company’s A-share employee stock-ownership schemes.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.0066 % to 6,371,685,824 shares, while treasury shares rose to 7,316,450. Total issued shares, including treasury holdings, remained unchanged at 6,379,002,274.

According to the disclosure, the buyback was duly authorised by the board and complied with all applicable listing rules and domestic regulations.